Ascendis Pharma A/S (ASND), on Friday, announced that its supplemental Biologics License Application seeking approval of Skytrofa in the proposed treatment of adults with growth hormone deficiency has been accepted for review by the FDA.
The U.S. regulatory agency's decision on the expanded label is expected on July 27, 2025.
Adult growth hormone deficiency is a condition with symptoms like central obesity, metabolic issues, low bone density, changes in cholesterol levels, and increased heart disease risk.
In a phase III trial, dubbed foresiGHt, adults with GHD treated with Skytrofa, showed a statistically significant reduction in trunk fat and an increase in total body lean mass at Week 38, compared to those receiving a placebo. Notably, the treatment was well tolerated, with no patients discontinuing due to adverse effects, further emphasizing its safety profile.
Skytrofa, a human growth hormone, was approved by the FDA for the treatment of pediatric growth hormone deficiency in 2021.
The product generated revenue of €138.5 million for the first nine months of 2024, a 21% year-over-year increase compared to €114.4 million during the same period of 2023.
For the full year 2024, Skytrofa is projected to generate revenue between €200 million and €220 million. Skytrofa revenue totaled €179 million in 2023.
ASND closed Thursday's trading at $130.64, down 2.71%. In premarket trading today, the stock is down 1.26% at $129.00.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.